Paltusotine hydrochloride is under clinical development by Crinetics Pharmaceuticals and currently in Pre-Registration for Acromegaly. According to GlobalData, Pre-Registration drugs for Acromegaly have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Paltusotine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paltusotine hydrochloride overview
Paltusotine hydrochloride (CRN-00808) is under development for the treatment of acromegaly and carcinoid syndrome. The drug candidate is administered through oral route in the form of tablet and capsule. The drug candidate is a biased nonpeptide acts by targeting somatostatin receptor type II (SSTR2).
The drug candidate was under development for age-related macular degeneration (AMD), diabetic retinopathy, acromegaly.
Crinetics Pharmaceuticals overview
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company that discovers, develops and commercializes novel therapeutics for endocrine diseases and endocrine-related tumors. The company’s pipeline products include paltusotine an oral somatostatin receptor type 2 (SST2) agonist that treats acromegaly and carcinoid syndrome; and CRN04894 an ACTH agonist that targets Cushing’s disease and congenital adrenal hyperplasia (CAH); PTH antagonist, SST3 agonist, SST5 agonist and TSH antagonist for hyperparathyroidism, polycystic kidney disease hyperinsulinism and graves’ disease; oral GLP-1 nonpeptide and oral GIP nonpeptide target diabetes and obesity. The company operates through its subsidiary in Australia. Crinetics Pharmaceuticals is headquartered in San Diego, California, the US.
For a complete picture of Paltusotine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
